REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 43 filers reported holding REATA PHARMACEUTICALS INC in Q3 2016. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,305,594 | +4420.8% | 22,595 | +4045.9% | 0.00% | – |
| Q1 2021 | $51,000 | +34.2% | 545 | +79.9% | 0.00% | – |
| Q4 2020 | $38,000 | +58.3% | 303 | +38.4% | 0.00% | – |
| Q3 2020 | $24,000 | -56.4% | 219 | -38.0% | 0.00% | – |
| Q2 2020 | $55,000 | -3.5% | 353 | -16.0% | 0.00% | – |
| Q1 2020 | $57,000 | -90.6% | 420 | -85.8% | 0.00% | – |
| Q4 2019 | $604,000 | +308.1% | 2,957 | +61.2% | 0.00% | – |
| Q3 2019 | $148,000 | -14.5% | 1,834 | +0.3% | 0.00% | – |
| Q2 2019 | $173,000 | +2783.3% | 1,829 | +2512.9% | 0.00% | – |
| Q1 2019 | $6,000 | -68.4% | 70 | -79.0% | 0.00% | – |
| Q4 2018 | $19,000 | +72.7% | 333 | +158.1% | 0.00% | – |
| Q3 2018 | $11,000 | +175.0% | 129 | +14.2% | 0.00% | – |
| Q2 2018 | $4,000 | -96.1% | 113 | -97.8% | 0.00% | – |
| Q2 2016 | $102,000 | – | 5,162 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $291,457,000 | 32.14% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 46,646 | $4,693,000 | 5.31% |
| Ikarian Capital, LLC | 471,400 | $47,423,000 | 3.34% |
| Duquesne Family Office | 695,033 | $69,927,000 | 2.27% |
| Camber Capital Management LP | 685,000 | $68,918,000 | 2.12% |
| LBJ Family Wealth Advisors, Ltd. | 30,359 | $3,054,000 | 1.82% |
| MADDEN SECURITIES Corp | 33,127 | $3,333,000 | 1.80% |
| Biondo Investment Advisors, LLC | 104,120 | $10,475,000 | 1.80% |
| Tolleson Wealth Management, Inc. | 60,750 | $6,112,000 | 1.73% |
| Keel Point, LLC | 97,074 | $9,767,000 | 1.26% |